NCT00198367View on ClinicalTrials.gov

Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

January 31, 2008

Study Completion Date

July 31, 2012

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Cisplatin-Gemzar

DRUG

Cisplatin-Navelbine-Radiotherapy

DRUG

Carboplatin-Taxol-Radiotherapy

Trial Locations (1)

Unknown

Centre Hospitalier Lyon-Sud - Radiotherapie/Oncologie, Pierre-Bénite

All Listed Sponsors

lead

Hospices Civils de Lyon

OTHER

NCT00198367 - Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter